CLINICAL_TRIALS
trial_result
· 2026-01-21
Clinical Trial Update: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) [Phase 3]
Summary
A Phase 3 study evaluating AL001 for frontotemporal dementia has been terminated, according to the latest trial update.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alector Inc. | Conditions: Frontotemporal Dementia | Phase 3 | Status: TERMINATED